Trial Profile

Phase 1B Trial of AV-MEL-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Antigens) With Anti-PD-1 Checkpoint Inhibitors in Metastatic Melanoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 13 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AVMEL 1 (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Granulocyte macrophage colony stimulating factor; Programmed cell death 1 receptor antagonists
Indications Malignant melanoma
Focus Adverse reactions
Acronyms AV-MEL-1 trial
Sponsors AiVita Biomedical

Most Recent Events

30 Apr 2025 Results assessing safety and efficacy of pembrolizumab plus personal dendritic cell vaccines in elderly patients with metastatic melanoma were presented at the 116th Annual Meeting of the American Association for Cancer Research.
07 Apr 2023 Planned End Date changed from 1 May 2024 to 1 May 2026.
07 Apr 2023 Planned primary completion date changed from 1 May 2022 to 1 May 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com